Citizens analyst Jason Butler raised the firm’s price target on Ironwood (IRWD) to $10 from $8 and keeps an Outperform rating on the shares. Ironwood reported Q4 financial results consistent with prior guidance and more importantly reiterated 2026 guidance including adjusted EBITDA of more than $300M, the analyst tells investors in a research note. The firm continues to believe that 2026 guidance supports LINZESS headwinds have passed, and the asset can drive substantial cash flow between now and the loss of brand exclusivity to fund current debt obligations and the apraglutide confirmatory trial/commercial launch.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
